Últimas noticias sobre Bristol-Myers Squibb (NYSE:BMY) Bolsa

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Exclusives

Trading Ideas

LUCY

Descubre cinco acciones en auge según el Índice Stock Whisper de Benzinga. ¿Cuál será la próxima gran oportunidad?

Cinco acciones prometedoras que merecen atención según el Índice Stock Whisper

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

BRISTOL MYERS SQUIBB ORD

Shares of Exelixis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exel#NASDAQ">EXEL</a>) have risen 20.7% in the past three months compared with the industry&#39;s growth of 6.3%. The stock has also outperformed the sector and the S&amp;P 500 Index.
Exelixis has been a consistent outperformer in the year so far on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress.
<h2>EXEL Outperforms Industry, Sector &amp; S&amp;P 500</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9a/80573.jpg?v=2113034342" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Cabometyx Boosts EXEL</h2>
Cabometyx maintained its status as the leading tyrosine kinase inhibitor (TKI) for the treatment of renal cell carcinoma (RCC) in 2023. This was mainly attributable to its use in combination with Bristol Myers&#39;&nbsp;Opdivo in the first-line setting. The drug also maintained growth in the hepatocellular carcinoma indication.
BMY&#39;s Opdivo is one of the leading immuno-oncology drugs, approved for various oncology indications.
Management is also focused on the label expansion of Cabometyx. The FDA accepted EXEL&#39;s supplemental new drug application (sNDA) for cabozantinib for patients with previously treated advanced pancreatic neuroendocrine tumors (pNET) and those with previously treated advanced extra-pancreatic NET (epNET). The FDA assigned a standard review with a target action date of April 3, 2025. The FDA also granted the orphan drug designation to cabozantinib for the treatment of pNET.
A potential label expansion should further propel its growth prospects.
Exelixis also intends to submit an sNDA with the FDA later this year for cabozantinib, in combination with Tecentriq (atezolizumab), for metastatic castration-resistant prostate cancer.
<h2>EXEL Makes Encouraging Pipeline Progress</h2>
The pipeline progress has been impressive as well, as Exelixis looks to expand its oncology portfolio beyond Cabometyx.
Other promising candidates in Exelixis&#39; pipeline zanzalintinib, a next-generation oral TKI and XL309. In the first half of 2025, Exelixis intends to initiate a phase III study, STELLAR-311, to evaluate zanzalintinib compared with everolimus as a first oral therapy in patients with pNET and epNET.
The company also plans to advance phase I efforts for XL309 and XB010.
EXEL decided to discontinue the development of XB002. It plans to reallocate resources to new pivotal trials with zanzalintinib, advancing XL309 and its growing pipeline.
The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug, Cabometyx.
<h2>Exelixis&#39; Efforts to Boost Shareholder Value</h2>
Exelixis is also making efforts to increase shareholder value through repurchases.&nbsp; At the end of the second quarter, Exelixis completed its 2024 share repurchase program, having repurchased 20.3 million shares of the company&#39;s common stock for a total of $450 million.
Consequently, the company returned $1 billion to shareholders since the initial $550 million stock repurchase program was authorized in March 2023.
The board of directors has authorized the repurchase of up to an additional $500 million of the company&#39;s common stock through the end of 2025.
<h2>Valuation &amp; Estimates</h2>
Going by the price/sales ratio, EXEL&#39;s shares currently trade at 3.64x forward sales, higher than its mean of 3.34x and the biotech industry&#39;s 1.79x.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/80575.jpg?v=206418566" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2024 earnings per share has increased to $1.83 from $1.79 over the past 30 days.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/37/80578.jpg?v=1325426803" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Conclusion</h2>
Large biotech companies are generally considered safe havens for investors interested in this sector. EXEL is a good stock to buy now, with good fundamentals and growth prospects.
The stock has performed well this year. Potential label expansion of Cabometyx should boost its growth. The company&#39;s efforts to expand its portfolio are encouraging as well. The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug, Cabometyx.
<h2>Zacks Rank &amp; Other Key Picks</h2>
EXEL currently carries a Zacks Rank #2 (Buy).&nbsp;
Some other top-ranked stocks in the biotech sector are Alnylam Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) and Krystal Biotech (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>), both carrying a Zacks Rank #1 (Strong Buy) at present.
ALNY&#39;s loss per share estimate for 2024 has narrowed from $1.20 to 63 cents in the past 60 days and the same for 2025 has narrowed from 34 cents to 27 cents.
Krystal Biotech&#39;s earnings per share for 2024 have increased to $2.38 from $1.98 in the past 90 days. Shares of KRYS have surged 42.8% year to date.
<a href="https://www.zacks.com/stock/news/2346907/exelixis-gains-20-7-in-three-months-is-this-the-right-time-to-buy?cid=CS-BENZ-FT-analyst_blog|rank_focused-2346907">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Large Cap

Mid Cap

News

Management

Markets

Analyst Ratings

General

ALNY

EXEL

KRYS

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

Barclays analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Underweight and raises the price target from $42 to $43.

Price Target

Barclays Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $43

Last week, the FDA approved&nbsp;Bristol Myers Squibb&nbsp;&amp; Co&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41073709/absence-of-black-box-warning-for-bristol-myers-schizophrenia-treatment-could-enhanc" rel="noreferrer noopener">schizophrenia in adults</a>.
Analysts at investment bank EF Hutton says, &#8220;This bodes well for Reviva&#8217;s Brilaroxazine, a multi-receptor-targeting antipsychotic that primarily focuses on serotonin (5-HT2A, 5-HT7), dopamine (D2, D3), and adrenergic receptors.&#8221;
Reviva Pharmaceuticals Holdings, Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208.
Last month, Reviva Pharmaceuticals released new vocal biomarker data from the Phase 3 RECOVER trial of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40770844/reviva-announces-new-vocal-biomarker-data-from-phase-3-recover-trial-of-brilaroxazine-in-schizophr" rel="noreferrer noopener">brilaroxazine in schizophrenia</a>.
Brilaroxazine demonstrated a strong efficacy for negative symptoms and other key symptoms of schizophrenia, such as total and positive symptoms, disorganization, and social functioning in the pivotal phase 3 RECOVER trial in schizophrenia.
The analyst notes that while Cobenfy primarily acts as a dopamine D2 partial agonist with limited serotonin receptor involvement, Brilaroxazine targets a broader range of receptors. This expanded activity could have a wider therapeutic impact, especially on cognitive symptoms.
The analyst further highlights that both Cobenfy and Brilaroxazine are effective in addressing the positive and negative symptoms of schizophrenia. However, Brilaroxazine&#8217;s action on the 5-HT7 receptor, which plays a crucial role in cognition, may offer added benefits in cognitive enhancement.
In terms of side effects, Cobenfy presents a more typical profile for second-generation antipsychotics, including risks of weight gain and metabolic issues. Brilaroxazine, on the other hand, is being developed to mitigate these metabolic concerns and minimize movement-related side effects.
The analyst concludes that Cobenfy and Brilaroxazine take distinct paths in treating schizophrenia. Both therapies offer value in the treatment landscape, but Brilaroxazine&#8217;s potential cognitive advantages and improved metabolic profile could give it an edge upon approval.
Price Action: Reviva Pharmaceuticals stock is down 4.8% at $1.19 at last check Monday.
Read next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41212461/whats-going-on-with-trump-media-technology-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Trump Media &amp; Technology Stock On Monday?</a></li>
</ul>

Analyst Color

Health Care

RVPH

Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst

11 analysts have shared their evaluations of Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.0, a high estimate of $59.00, and a low estimate of $41.00. This current average reflects an increase of 2.32% from the previous average price target of $46.91. 
<img src="https://www.benzinga.com/files/images/story/2024/1728324046_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Bristol-Myers Squibb by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Scala</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$59.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$53.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$51.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$42.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Steve Scala</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$53.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$45.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bristol-Myers Squibb. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bristol-Myers Squibb compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bristol-Myers Squibb's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bristol-Myers Squibb's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BMY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bristol-Myers Squibb analyst ratings.</a>
<h2>About Bristol-Myers Squibb</h2>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
<h3>Key Indicators: Bristol-Myers Squibb's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Bristol-Myers Squibb showcased positive performance, achieving a revenue growth rate of 8.69% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.77%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Bristol-Myers Squibb's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 10.03%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Bristol-Myers Squibb's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.73%, the company showcases efficient use of assets and strong financial health.
Debt Management: Bristol-Myers Squibb's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.17.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 11 Analyst Insights On Bristol-Myers Squibb

TD Cowen analyst Steve Scala maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Hold and raises the price target from $53 to $59.

TD Cowen Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $59

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$20.00</td>
<td>$41.4K</td>
<td>389</td>
<td>5.5K</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$260.00</td>
<td>$25.2K</td>
<td>849</td>
<td>1.4K</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$190.00</td>
<td>$27.6K</td>
<td>4.0K</td>
<td>718</td>
</tr>
<tr>
<td>NVCR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$13.00</td>
<td>$27.6K</td>
<td>110</td>
<td>691</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$490.00</td>
<td>$30.8K</td>
<td>250</td>
<td>161</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$39.1K</td>
<td>6.6K</td>
<td>113</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$70.7K</td>
<td>2.6K</td>
<td>92</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$32.2K</td>
<td>1.8K</td>
<td>66</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$100.00</td>
<td>$26.7K</td>
<td>420</td>
<td>59</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$600.00</td>
<td>$40.6K</td>
<td>464</td>
<td>51</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bullish sentiment. It expires in 4 day(s) on October 11, 2024. Parties traded 901 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $41.4K, with a price of $46.0 per contract. There were 389 open contracts at this strike prior to today, and today 5520 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option trade with bullish sentiment. It expires in 4 day(s) on October 11, 2024. Parties traded 120 contract(s) at a $260.00 strike. The total cost received by the writing party (or parties) was $25.2K, with a price of $210.0 per contract. There were 849 open contracts at this strike prior to today, and today 1476 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a put option sweep that happens to be bullish, expiring in 11 day(s) on October 18, 2024. This event was a transfer of 60 contract(s) at a $190.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $460.0 per contract. There were 4070 open contracts at this strike prior to today, and today 718 contract(s) were bought and sold. 
• For NVCR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>), we notice a put option sweep that happens to be bearish, expiring in 11 day(s) on October 18, 2024. This event was a transfer of 690 contract(s) at a $13.00 strike. This particular put needed to be split into 63 different trades to become filled. The total cost received by the writing party (or parties) was $27.6K, with a price of $40.0 per contract. There were 110 open contracts at this strike prior to today, and today 691 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bullish, expiring in 39 day(s) on November 15, 2024. This event was a transfer of 16 contract(s) at a $490.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $30.8K, with a price of $1930.0 per contract. There were 250 open contracts at this strike prior to today, and today 161 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 466 day(s) on January 16, 2026. Parties traded 44 contract(s) at a $50.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $890.0 per contract. There were 6607 open contracts at this strike prior to today, and today 113 contract(s) were bought and sold. 
• For SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we notice a put option trade that happens to be bearish, expiring in 102 day(s) on January 17, 2025. This event was a transfer of 68 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $70.7K, with a price of $1040.0 per contract. There were 2682 open contracts at this strike prior to today, and today 92 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bearish sentiment. It expires in 466 day(s) on January 16, 2026. Parties traded 43 contract(s) at a $45.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $750.0 per contract. There were 1834 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a put option sweep with bullish sentiment. It expires in 347 day(s) on September 19, 2025. Parties traded 50 contract(s) at a $100.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.7K, with a price of $535.0 per contract. There were 420 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option trade that happens to be bullish, expiring in 466 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $40.6K, with a price of $2030.0 per contract. There were 464 open contracts at this strike prior to today, and today 51 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

NVCR

SAVA

10 Health Care Stocks Whale Activity In Today's Session

Goldman Sachs upgraded its 12-month price target for the S&amp;P 500 index from 5,600 to 6,300, driven by stronger-than-expected corporate earnings heading into the third quarter and robust demand <a href="https://www.benzinga.com/topic/artificial-intelligence">for artificial intelligence technologies. </a>
The revision, outlined in a report led by U.S. equity strategist David Kostin, reflects optimism around earnings-per-share (EPS) growth and margin expansion, particularly in key sectors like technology and healthcare.
The S&amp;P 500, which tracks the largest 500 U.S. corporations through the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), is currently trading less than 1% below its all-time high.
<h3 class="wp-block-heading">S&amp;P 500 Earnings Forecasts Upwardly Revised</h3>
Goldman Sachs now projects the S&amp;P 500&#8217;s earnings per share to rise to $268 in 2025, representing an 11% year-over-year increase. 
&#8220;The primary driver of the upward revision to our 2025 EPS estimate is greater margin expansion,&#8221; analysts wrote. 
This is up from the bank&#8217;s previous estimate of $256, which forecasted just 6% growth. For 2026, the investment bank forecasts further EPS growth to $288, or 7%, continuing a healthy upward trajectory.
For the current year, Goldman Sachs maintains its full-year EPS forecast of $241 for the S&amp;P 500, reflecting an 8% year-over-year growth, consistent with prior guidance.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Year</th>
<th>Goldman Sachs&#8217; S&amp;P 500 EPS Forecast</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024</td>
<td>$241</td>
<td>+8%</td>
</tr>
<tr>
<td>2025</td>
<td>$268</td>
<td>+11%</td>
</tr>
<tr>
<td>2026</td>
<td>$288</td>
<td>+7%</td>
</tr>
</tbody>
</table>
</figure>
Goldman Sachs' earnings forecasts are supported by steady macroeconomic growth expectations. 
The firm's economists predict that U.S. GDP will grow by 2.3% in 2025, followed by a 2.0% expansion in 2026. 
Despite inflationary pressures, the bank expects companies to maintain pricing power, which should help them offset rising labor and input costs.
<h3 class="wp-block-heading">AI and Semiconductor Recovery Boost IT Sector Outlook</h3>
A key driver behind Goldman Sachs' more bullish outlook is the increasing role of AI and the recovery in the semiconductor sector. 
According to the report, semiconductor shipments—excluding memory chips—are currently about 10% below their historical trend. 
As this shortfall reverses, the firm anticipates stronger margins for the industry, contributing approximately $7, or 20%, of the S&amp;P 500&#8217;s EPS growth in 2025.
The investment bank also highlighted the ongoing strength in mega-cap tech firms, such as Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
These companies have consistently delivered quarterly earnings surprises, with an average beat of 9% over the past four quarters.
Goldman Sachs noted that &#8220;while the magnitude of beats may moderate,&#8221; there is &#8220;strong ongoing AI demand that should benefit these stocks.&#8221;
<h3 class="wp-block-heading">Margin Expansion To Power 2025 Gains</h3>
Goldman Sachs has revised its expectations for S&amp;P 500 net margin expansion in 2025, now forecasting a 78 basis point increase compared to its earlier estimate of just 24 basis points. This enhanced margin outlook stems largely from a more favorable macroeconomic environment, where input costs are expected to rise at a slower pace than the prices charged by companies, thus widening margins.
One key factor behind the forecasted margin gains is the normalization of certain one-off expenses that have weighed heavily on corporate earnings in 2024. 
For instance, in the healthcare sector, companies like Bristol-Myers Squibb Co.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) were significantly impacted by high R&amp;D-related charges earlier in the year. 
Goldman Sachs predicts these expenses will moderate in 2025, leading to an $83 boost in healthcare margins alone, contributing to a broader EPS uplift.
<h3 class="wp-block-heading">Downside, Upside Scenarios And Short-Term Targets</h3>
If economic growth slows more than expected, the S&amp;P 500's price-to-earnings (P/E) ratio could compress to 18x, which would imply a price target of 5,400—about 6% lower than current levels. Additionally, uncertainty surrounding U.S. monetary policy and the outcome of the 2024 election could lead to increased market volatility.
On the upside, if the P/E ratio remains stable at 22x, the index could climb to 6,600 in the next 12 months. In a more optimistic scenario, where economic growth remains robust and investor sentiment improves, Goldman Sachs suggests the P/E ratio could rise to 23x, pushing the S&amp;P 500 to 6,900 by year-end 2025.
For the remainder of 2024, Goldman Sachs expects the S&amp;P 500 to experience some volatility as investors weigh the implications of the Federal Reserve&#8217;s policy stance and the upcoming presidential election. 
The bank sees limited downside risks and has set a three-month price target of 6,000 for the index, up from a previous target of 5,600. Over the next six months, Goldman expects the index to reach 6,100.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41191633/us-energy-stocks-notch-biggest-weekly-gains-in-2-years-exxon-hits-record-highs-as">US Energy Stocks Notch Biggest Weekly Gains In 2 Years, Exxon Hits Record Highs As Crude Surges To $75 On Israel-Iran Jitters</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Broad U.S. Equity ETFs

Tech

ETFs

AAPL

GILD

GOOG

GOOGL

MSFT

NVDA

VRTX

S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) may have been a hero in the COVID-19 vaccine race, but its stock is stuck in the slow lane. Down nearly 14% over the last year, the pharma giant's shares have struggled as demand for its pandemic-related treatments <a href="https://www.benzinga.com/quote/PFE/news">has fizzled out</a>.
But things could get interesting—activist investor Starboard Value just acquired a $1 billion stake in the company.
Could this signal a turning point for the pharma giant?
<h2 class="wp-block-heading">Starboard To The Rescue?</h2>
Starboard Value, led by Jeff Smith, isn't shy about shaking things up. The fund has taken a front-row seat in Pfizer's boardroom drama, enlisting ex-Pfizer heavyweights Ian Read and Frank D'Amelio to help revitalize the company's sagging fortunes. 
Starboard is no stranger to taking control and pushing for value, having previously pressured giants like Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) and Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
Pfizer's stock performance has been far from thrilling this year, with shares down 3.87% year-to-date. 
In contrast, the S&amp;P 500 has surged over 21%, making Pfizer look like the laggard of the pack. Starboard's involvement might be the catalyst Pfizer needs, but investors should be cautiously optimistic.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41112790/pfizer-divests-3-3b-stake-in-sensodyne-toothpaste-and-panadol-painkiller-maker-haleon">Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon</a>
<h2 class="wp-block-heading">The Charts Say It's Bearish—For Now</h2>
Pfizer's stock charts aren&#8217;t painting a rosy picture. The stock is sitting below its five-, 20- and 50-day exponential moving averages (EMAs), signaling a strong bearish trend.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="459" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07070043/Screenshot-2024-10-07-at-4.15.52-PM.png" alt="" class="wp-image-583111" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07070043/Screenshot-2024-10-07-at-4.15.52-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07070043/Screenshot-2024-10-07-at-4.15.52-PM-300x219.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The eight-day simple moving average (SMA) is $28.72, while the stock lingers at $28.58—a clear bearish signal.
The 200-day SMA, however, tells a slightly different story, coming in at $28.17. With Pfizer's share price slightly above that long-term average, there's a glimmer of hope for a bullish reversal.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="459" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07070043/Screenshot-2024-10-07-at-4.15.11-PM.png" alt="" class="wp-image-583112" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07070043/Screenshot-2024-10-07-at-4.15.11-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/07070043/Screenshot-2024-10-07-at-4.15.11-PM-300x219.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100724&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Pfizer stock&#8217;s Moving Average Convergence/Divergence (MACD) is negative 0.14, reinforcing the bearish momentum.
However, its Relative Strength Index (RSI) stands at 42.63, suggesting that while the stock has faced selling pressure, it hasn't yet reached oversold conditions. Unless momentum shifts further downward, a rush of buyers may remain uncertain.
<h2 class="wp-block-heading">What's The Buzz With Starboard?</h2>
Starboard's game plan could be just what Pfizer needs to turn the tide. With Pfizer's COVID-19 products no longer dominating, the company has shifted its focus toward oncology, betting big on cancer treatments. Pfizer spent $43 billion on the cancer drugmaker Seagen, banking on its pipeline to generate blockbuster medicines.
Yet, the market remains skeptical. The big question: Can Pfizer replicate its COVID-19 mRNA success in the battle against cancer? Only time will tell. For now, the company&#8217;s oncology efforts are more of a long-term bet than an immediate fix.
<h2 class="wp-block-heading">Waiting For A Turnaround</h2>
Technically, Pfizer is in bearish territory, but with Starboard&#8217;s recent move and a strategy shift towards oncology, the stock could be gearing up for a turnaround. Investors should keep a close eye on the $1 billion infusion from Starboard and whether their playbook sparks bullish momentum. F
or now, the stock remains under pressure, but a rebound might be lurking on the horizon.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41203264/wall-street-set-to-start-new-week-sharply-lower-as-traders-brace-for-key-economic-data-and-fed-minu">Wall Street Set To Start New Week Sharply Lower As Traders Brace For Key Economic Data And Fed Minutes: Why Strategist Sees Market Consolidating In Near Term</a></li>
</ul>
Photo: Shutterstock

Technicals

Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?

On Thursday, the FDA approved Bristol Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo&nbsp;(nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor&nbsp;receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy,&nbsp;followed by single-agent&nbsp;Opdivo&nbsp;as adjuvant <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41176061/u-s-food-and-drug-administration-approves-perioperative-treatment-of-neoadjuvant-opdivo-nivolumab-" rel="noreferrer noopener">treatment after surgery</a>.
The approval is based on results from the CheckMate-77T trial, the company&#8217;s second Phase 3 trial with an immunotherapy-based combination for resectable NSCLC.
Opdivo&nbsp;is now the only PD-1 inhibitor to demonstrate statistically significant and clinically meaningful benefits in this disease versus chemotherapy in both a neoadjuvant-only regimen and as part of a perioperative regimen.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41028913/bristol-myers-2seventy-bio-halt-phase-3-trial-for-abecma-in-newly-diagnosed-myeloma" rel="noreferrer noopener">Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability</a>.
The risk of disease recurrence, progression, or death was reduced by 42% in patients treated in the&nbsp;Opdivo&nbsp;arm, compared to the chemotherapy and placebo arm, with a median follow-up of 25.4 months.
In addition, 18-month event-free survival (EFS) was demonstrated in 70% of patients in the&nbsp;Opdivo&nbsp;arm, compared to 50% in the chemotherapy and placebo arm.
Furthermore, 25% of patients in the&nbsp;Opdivo&nbsp;arm achieved pathologic response (pCR) in the intent-to-treat population, while 4.7% of patients in the comparator arm achieved pCR.
As the U.S. pharma giant seeks to cover itself from the patent cliff related to top-selling drugs Eliquis (apixaban) and Opdivo (nivolumab), the company recently received FDA approval for Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41073709/absence-of-black-box-warning-for-bristol-myers-schizophrenia-treatment-could-enhanc" rel="noreferrer noopener">schizophrenia in adults</a>.
As per its <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/14272/000001427224000044/bmy-20231231.htm" rel="noreferrer noopener">latest</a> 10K filing, Eliquis&#8217; U.S. patent is expected to expire in 2026.
Opdivo&#8217;s U.S. patent loss is expected in 2028, Europe in 2030, and Japan in 2031.
Another cancer drug, Yervoy&nbsp;(ipilimumab), is expected to lose market exclusivity in 2025 in the U.S. and Japan and 2026 in Europe.
Price Action: BMY stock is down 1.07% at $53.62 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41173172/orthopedic-implant-player-enovis-m-a-strategy-core-to-growth-and-competitiveness-an" target="_blank" rel="noreferrer noopener">Orthopedic Implant Player Enovis&#8217; M&amp;A Strategy Core To Growth And Competitiveness, Analyst Says</a>.</li>
</ul>
Photo via Shutterstock

Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting

Bristol Myers Squibb Says FDA Approved Perioperative Treatment Of Neoadjuvant Opdivo (Nivolumab) And Chemotherapy Followed By Surgery And Adjuvant Single-Agent Opdivo For Resectable Non-Small Cell Lung Cancer

FDA Approves Neoadjuvant/Adjuvant Nivolumab For Resectable Non-small Cell Lung Cancer

Investors with a lot of money to spend have taken a bearish stance on Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BMY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Bristol-Myers Squibb.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 53%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $265,783, and 10 are calls, for a total amount of $657,729.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $70.0 for Bristol-Myers Squibb over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Bristol-Myers Squibb's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers Squibb's whale trades within a strike price range from $40.0 to $70.0 in the last 30 days. 
<h3>Bristol-Myers Squibb Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727806573_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.99</td>
<td>$2.92</td>
<td>$2.91</td>
<td>$52.50</td>
<td>$145.4K</td>
<td>15.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.92</td>
<td>$2.89</td>
<td>$2.92</td>
<td>$52.50</td>
<td>$142.7K</td>
<td>15.7K</td>
<td>548</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$8.15</td>
<td>$7.95</td>
<td>$8.15</td>
<td>$57.50</td>
<td>$73.3K</td>
<td>17</td>
<td>92</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.85</td>
<td>$4.6</td>
<td>$4.6</td>
<td>$52.50</td>
<td>$69.0K</td>
<td>2.5K</td>
<td>188</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$49.00</td>
<td>$67.3K</td>
<td>7.1K</td>
<td>182</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Following our analysis of the options activities associated with Bristol-Myers Squibb, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Bristol-Myers Squibb</h3>
<ul>
<li>Currently trading with a volume of 8,110,986, the BMY's price is up by 1.88%, now at $52.72. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 30 days.</li>
</ul>
<h3>What The Experts Say On Bristol-Myers Squibb</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $50.333333333333336.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has decided to maintain their Market Perform rating on Bristol-Myers Squibb, which currently sits at a price target of $53. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $50. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Market Perform rating for Bristol-Myers Squibb, targeting a price of $48. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Bristol-Myers Squibb with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On Bristol-Myers Squibb

On Tuesday, IGM Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41103117/igm-biosciences-announces-strategic-pivot-to-focus-exclusively-on-autoimmunity" rel="noreferrer noopener">for autoimmune diseases</a>.
The company&#8217;s lead candidates include imvotamab, which is being developed for rheumatoid arthritis, systemic lupus erythematosus, and myositis, and IGM-2644, which is expected to enter a clinical study for generalized myasthenia gravis by the end of 2024.
IGM to minimize future spending on aplitabart and other oncology candidates.&nbsp;
In light of the emerging data from the company&#8217;s ongoing randomized clinical trial of aplitabart in second-line metastatic colorectal cancer, together with the significant opportunity in autoimmunity, the company has decided to reduce workforce and minimize its future spending on the research and clinical development of aplitabart and other oncology candidates.
The company expected to release aplitabart top-line progression-free survival results from randomized colorectal cancer trial by the end of the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40362024/igm-biosciences-announces-second-quarter-2024-financial-results-and-provides-corporate-update" rel="noreferrer noopener">first quarter of 2025</a>.
As a result of these actions, IGM believes it can extend its current cash runway into 2027.
As part of the company&#8217;s strategic pivot to autoimmunity, Fred Schwarzer, CEO, President, and Director, and Bruce Keyt, chief scientific officer, will step down from their current roles.
IGM has appointed ex-Bristol Myers Squibb &amp; Co&#8217;s executive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Mary Beth Harler as the CEO.
Chris Takimoto, Chief Medical Officer, has also announced to step down.
Price Action: IGMS stock is down 13.20% at $14.36&nbsp;at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41118751/eli-lilly-eyes-new-trials-for-weight-loss-drugs-in-non-obese-patients" target="_blank" rel="noreferrer noopener">Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients</a>.</li>
</ul>

Movers

IGMS

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

Edgewise Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ewtx#NASDAQ">EWTX</a>) is a small-cap <a href="https://www.marketbeat.com/compare-stocks/pharmaceutical-stocks/">pharmaceutical stock</a> that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks. Yet, with still only a market cap of $2.4 billion, is there still time to get in? I&#39;ll examine recent news around the company, its <a href="https://edgewisetx.com/science-pipeline/pipeline/">drug pipeline</a>, and what Wall Street is saying to get a better handle on this question.
<h3>Edgewise&#39;s Muscular Dystrophy Treatments Have Large Market Than Others</h3>
Edgewise currently has two drugs that are driving the company. They are Sevasemten and EDG-7500. The company is researching Sevasemten to treat muscular dystrophy (MD). One interesting thing about this medicine is that it is being researched to treat multiple types of MD.
Specifically, it is currently in Phase 3 trials to treat Becker MD and in Phase 2 trials for Duchenne MD. Many medicines are being researched only on one form of MD. So, the possibility that they could apply to both is a strong differentiator for the company.
However, this is likely because the treatment manages symptoms. It does not target the genetic cause of Duchenne MD. The root cause of Duchenne and Becker is different, but the symptoms are similar.
Still, this treatment could be valuable and could theoretically be used in conjunction with genetic treatments. The focus on treatment management opens the product up to the entire MD market rather than a sliver of it; another potential benefit.
In its latest results for Becker, the drug showed it actually slightly improved muscle function after 24 months. Those given a placebo showed significantly worse function. Becker MD currently has no approved treatments. The company estimates there are currently around 47,000 people with one of the diseases in the US, EU, and Japan combined.
<h3>&nbsp;EDG-7500 Results Show It Keeps Up With The Competition</h3>
The company&#39;s other main drug, EDG-7500, is a cardiovascular medicine. Specifically, it works to treat hypertrophic cardiomyopathy (HCM). Recent good news around this drug was why shares of Edgewise <a href="https://www.marketbeat.com/stock-ideas/edgewise-therapeutics-soars-50-key-reasons-behind-the-surge/">jumped 50% in one day</a>. HCM primarily affects the left ventricle of the heart, causing its walls to thicken. The left ventricle is the main pumping station of the heart. pumped. The thickening makes it hard for the left ventricle to pump blood and can result in heart failure.
On average, the study revealed that a biomarker linked to heart stress decreased by 64%. Another measurement of how well the heart is pumping blood is the left ventricular ejection fraction (LVEF).
The results showed that all the patients maintained a normal level of LVEF. Thus, the treatment reduced stress on the heart without interfering with its ability to pump. The market for this treatment is much larger, affecting up to 630,000 people in the United States alone.
However, HCM does have an approved treatment: <a href="https://www.marketbeat.com/stocks/NYSE/BMY/">Bristol Myers Squibb&#39;s (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) Camzyos. The drug showed a <a href="https://news.bms.com/news/corporate-financial/2022/Mavacamten-Demonstrated-Significant-Reduction-in-Need-for-Septal-Reduction-Therapy-in-Symptomatic-Obstructive-HCM-Patients-in-Phase-3-VALOR-Trial/default.aspx#:~:text=Improvement%20in%20biomarkers%20of%20cardiac,greater%20(p%3C0.0001).">67% reduction</a> in the same biomarker as EDG-7500. However, a very small number of patients did see their LVEF levels fall below normal. At this point, the drugs appear to have similar levels of safety and efficacy. Two and a half years ago, Camzyos received approval. It generated $139 million last quarter, up by 184% from the previous year.
<a href="https://www.marketbeat.com/stocks/NASDAQ/CYTK/">Cytokinetics&#39; (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/cytk#NASDAQ">CYTK</a>) aficamten, another competitor, is further along but has yet to receive approval. <a href="https://www.fiercebiotech.com/biotech/edgewise-therapeutics-heart-med-candidate-sends-shares-soaring-early-data">According to Fierce Biotech</a>, analysts at Mizuho Securities say the results of the two drugs look similar.
When it comes to Wall Street, several analysts still see significant upside in Edgewise. At least four firms have increased their price targets on Edgewise since it released Phase 2 results for EDG-7500.
Based on the average of those four targets, the implied upside of Edgewise is 55%, based on the Sept. 24 closing price of nearly $26. The most bullish analyst, Wedbush, thinks Edgewise could rise 70%.
<h3>Final Thoughts On Edgewise</h3>
At the end of the day, the party is certainly not over for Edgewise until it is. More good news about the drug treatments would continue to boost the stock price. But, it will take a long time for sales to justify its high valuation. The probability of treatments getting approved is low, at around <a href="https://www.cbo.gov/publication/57126#:~:text=Only%20about%2012%20percent%20of,than%20%242%20billion%20per%20drug.">12% on average</a>.
The results of EDG-7500 do show promise not only in their comparability to the already approved treatment but also in the revenue that Bristol-Myers has demonstrated. However, with Sevasemten in Phase 3 trials for Becker MD, the company could be the first to get an approved treatment in that market.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/analyst-think-theres-still-time-to-get-in-on-edgewise-up-332/">Analysts Think There&#39;s Still Time to Get in on Edgewise, Up 332%</a>&quot; first appeared on MarketBeat.

Small Cap

CYTK

EWTX

Analysts Think There's Still Time To Get In On Edgewise

On Monday, Prime Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) announced a strategic research collaboration and license agreement with Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;to develop reagents for the next generation of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41088429/prime-medicine-announces-strategic-research-collaboration-and-license-agreement-with-bristol-myers" rel="noreferrer noopener">ex vivo</a><a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41088429/prime-medicine-announces-strategic-research-collaboration-and-license-agreement-with-bristol-myers" rel="noreferrer noopener"> T-cell therapies</a>.
Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35148656/preclinical-phase-firm-prime-medicines-gene-editing-platform-has-potential-analyst" rel="noreferrer noopener">Preclinical-Phase Firm Prime Medicine&#8217;s Gene Editing Platform Has Potential: Analyst</a>.
Bristol Myers Squibb will be responsible for developing, manufacturing, and commercializing next-generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development.
Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb.
Prime Medicine is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 billion in development milestones and more than $2.1 billion in commercialization milestones, along with royalties on net sales.
Concurrently, Prime Medicine announced that it would <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41088559/prime-medicine-unveils-strategically-focused-pipeline" rel="noreferrer noopener">streamline its pipeline</a>.
The company said it will focus on developing two programs for chronic granulomatous disease (CGD).
<ul>
<li>PM359, an ex vivo autologous hematopoietic stem cell (HSC) product: The company has initiated a Phase 1/2 clinical trial to assess the safety, biological activity, and preliminary efficacy of PM359 in adult and pediatric patients and expects initial clinical data study in 2025.</li>
<li>Ex vivo HSC product for the treatment of X-linked CGD</li>
</ul>
Other candidates that the company will prioritize include:
<ul>
<li>Lipid nanoparticle (LNP) Prime Editor for Wilson&#8217;s Disease: Prime Medicine expects to present new preclinical data and initiate IND-enabling activities in the fourth quarter of 2024 and intends to file an IND and/or clinical trial application in the first half of 2026. </li>
<li>LNP / adeno-associated virus Prime Editors for the treatment of Cystic Fibrosis.</li>
</ul>
With the $110 million upfront consideration received from Bristol Myers Squibb under the strategic research collaboration and license agreement announced this morning, Prime Medicine expects its cash runway to fund operations into the first half of 2026.
Prime Medicine is identifying partnership opportunities to advance its other programs, including those for neurological diseases, cell therapy, ocular diseases, and hearing loss.
Price Action: PRME stock is up 17.1% at $4.05 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41089672/whats-going-on-with-alibaba-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Alibaba Stock On Monday?</a></li>
</ul>

Contracts

PRME

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology.
Bristol Myers Squibb will be responsible for development, manufacturing and commercialization of the next generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development.

Prime Medicine Enters Strategic Research Collaboration And License Agreement With Bristol Myers Squibb; Prime Medicine To Receive $110M Upfront, With Potential For More Than $3.5B In Milestones

On Thursday, the FDA approved&nbsp;Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">schizophrenia in adults</a>.
BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for Bristol Myers shares.
The analyst notes that given that many prior antipsychotic medications received black box warnings due to increased mortality risks, particularly in elderly patients, Cobenfy&#8217;s absence of such a warning could significantly enhance its potential in treating Alzheimer&#8217;s related-psychosis, pending further clinical trials.
BMO projects peak sales of $2.4 billion for Cobenfy in schizophrenia and $3.9 billion in Alzheimer&#8217;s related-psychosis, raising the price target to $53 from $48, with a <a target="_blank" href="https://www.benzinga.com/quote/BMY/analyst-ratings" rel="noreferrer noopener">Market Perform rating</a>.
The analyst notes that Cobenfy will be priced at $1,850 for a 30-day supply or $22,500/year, representing a discount to previous expectations.
Truist Securities highlights that AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is also advancing emraclidine as a treatment for schizophrenia and Alzheimer&#8217;s disease-related psychosis.
According to Truist analysts, emraclidine differs from KarXT in its mechanism of action.
Despite emerging competition, Truist points out that KarXT holds a first-mover advantage and is ahead by at least two to three years.
Truist maintains the Buy rating and a price target of $62.
William Blair projects peak U.S. sales for Cobenfy to reach approximately $2 billion by 2030, driven solely by its use in treating schizophrenia.
However, if the drug is approved for additional indications, such as Alzheimer-related psychosis and adjunctive schizophrenia—both currently in Phase 3 trials—annual sales could rise to around $3 billion to $5 billion, pending positive results.
The analyst points out that although the label lacks a black box warning, it does include caution for urinary retention, elevated heart rate, reduced gastric motility, and angioedema.
Price Action: BMY stock is up 2.33% at $51.29&nbsp;at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41070911/fda-removes-clinical-hold-on-biomea-fusions-early-stage-trials-for-potential-diabetes-candidate" target="_blank" rel="noreferrer noopener">FDA Removes Clinical Hold On Biomea Fusion&#8217;s Early-Stage Trials For Potential Diabetes Candidate</a>.</li>
</ul>

ABBV

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

In the Phase 3b/4 PSORIATYK SCALP trial Sotyktu was superior to placebo across all primary and secondary endpoints at Week 16, with patients reporting significantly greater improvement in symptoms
Safety profile in PSORIATYK SCALP was consistent with the established safety profile of Sotyktu
In the real-world RePhlect registry of patients, six months of Sotyktu treatment was consistent with the efficacy outcomes observed in the POETYK clinical studies for psoriasis
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54127020&amp;newsitemid=20240925005092&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=bea69efca57c5230176a4c6a25a3865c">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced positive results from the Phase 3b/4 PSORIATYK SCALP trial evaluating Sotyktu (deucravacitinib) for the treatment of patients with moderate-to-severe scalp psoriasis, including those with less extensive overall psoriasis. The primary endpoint was met, with a statistically significant improvement in the scalp-specific Physician's Global Assessment (ss-PGA) response of 0 or 1 (clear/almost clear) at 16 weeks, with more than three times as many patients achieving ss-PGA 0/1 with Sotyktu treatment compared to those on placebo (48.5% versus 13.7%, respectively; p&lt;0.0001).
The new PSORIATYK SCALP efficacy and safety results (oral presentation FC04.07, abstract #5627), patient-reported outcomes (oral presentation FC06.06, abstract #5390) and 23 additional abstracts are being presented at the European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, Netherlands taking place September 25-28, 2024.

Bristol Myers Squibb Presents New Data From 2-Trials Demonstrating Sotyktu Efficacy In both Moderate-To-Severe Scalp Psoriasis And In A Real-World Setting; In The Phase 3b/4 PSORIATYK SCALP Sotyktu Was Superior To Placebo Across All Primary And Secondary Endpoints At Week 16, With Patients Reporting Significantly Greater Improvement In Symptoms

BMO Capital analyst Evan Seigerman maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Market Perform and raises the price target from $48 to $53.

BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Raises Price Target to $53

In August, the Federal Reserve's preferred inflation gauge, the <a href="https://www.benzinga.com/news/econ-s/24/09/41066122/feds-preferred-inflation-gauge-comes-in-below-expectations-for-august-easing-concerns-about-rising-p">Personal Consumption Expenditures </a>(PCE) Price Index, rose 2.2% year-over-year, coming in below analyst expectations of 2.3%. That&#8217;s down from July's 2.5%.
The core PCE, which excludes volatile food and energy prices, increased by 2.7% year-over-year, matching forecasts and slightly higher than July's 2.6%.
This decline in overall inflation, despite steady core inflation, suggests a potential easing of price pressures, even as costs for services like housing and financial services continue to rise.
Also Read: <a href="https://www.benzinga.com/markets/equities/24/09/41063577/peter-thiel-offloads-over-1b-in-palantir-stock-in-2024-as-stock-more-than-doubles">Peter Thiel Offloads Over $1B In Palantir Stock In 2024 As Stock More Than Doubles</a>
Following Friday&#8217;s PCE report, these 14 stocks showed strong momentum in premarket trading, according <a href="https://pro.benzinga.com/">to Benzinga Pro:</a>
<ul>
<li>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) rises 3.6% to $51.94.</li>
<li>PPD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) climbs 3.8% to $134.14.</li>
<li>JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is up 3.3% to $39.38.</li>
<li>Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) gains 2.8% to $24.89.</li>
<li>Anheuser-Busch InBev SA/NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>) advances 1.5% to $66.52.</li>
<li>NetEase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) lifts 1.7% to $92.69.</li>
<li>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) jumps 1.3% to $14.00.</li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rockets 1.1% to $257.16.</li>
<li>Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) moves 0.9% higher to $105.80.</li>
<li>BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) ticks up 0.9% to $31.07.</li>
<li>PayPal Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) soars 1.1% to $81.03.</li>
<li>General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) inches up 0.9% to $46.24.</li>
<li>Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) posts a rise of 1.07% to $185.01.</li>
<li>Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) registers a boost of 0.7% to $110.69.</li>
</ul>
Rising costs in services, particularly in housing, financial services, and insurance, were the key drivers of inflation, pushing the overall PCE index higher. While service prices surged, goods prices saw a slight decline, helping to offset some of the inflationary pressure. Meanwhile, falling energy prices, especially gasoline, provided additional relief compared to previous periods of stronger inflationary impact from energy.
Food prices increased modestly, primarily in off-premises consumption like groceries, but their effect on inflation was smaller compared to services. 
Core inflation, which excludes food and energy, remained steady due to ongoing price increases in durable goods and essential services. Despite minor declines in goods prices, rising service costs <a href="https://www.benzinga.com/topic/inflation">kept core inflation elevated</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/09/41066338/alibaba-jd-com-strike-deal-to-open-ecosystems-amid-slowing-growth-and-chinas-antitrust-pressure">Alibaba, JD.com Strike Deal To Open Ecosystems Amid Slowing Growth And China&#8217;s Antitrust Pressure</a></li>
</ul>
Photo: Shutterstock.

Econ #s

BABA

EQNR

NTES

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PYPL

TSLA

14 Stocks Gain Momentum As August Inflation Comes In Below Expectations

AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia

The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst economic shifts, rising chronic illnesses, and strong growth projections in global revenues and biotechnology markets. Therefore, it could be wise to invest in pharma stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead Sciences (GILD), which could lead the next drug revolution. Read more... The pharmaceutical industry is driving the next drug revolution with AI and biotech innovations. Companies are using automation to streamline processes, boosting productivity and accuracy. Investors favor the sector for its steady profits, resilience during economic shifts, and sustained demand, driven by factors such as rising chronic illnesses.
Amid this favorable backdrop, investors could consider buying fundamentally strong pharmaceutical stocks: AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>).
In today's digital era, pharmaceutical firms are rapidly embracing AI to enhance biopharma manufacturing, drug development, and healthcare solutions. AI and machine learning are revolutionizing drug discovery, personalizing treatments, and boosting efficiency. Global pharmaceutical revenues are projected to reach $1.16 trillion this year, with a <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">6.2% CAGR</a>, also reaching $1.47 trillion by 2028.
In addition, advancements in biopharmaceuticals and biomedical science are driving cutting-edge therapies, such as cell and gene therapies, stem cell technologies, and regenerative and precision medicines. These innovations are propelling the pharmaceutical industry's growth, with the global biotechnology market projected to reach <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">$3.88 trillion by 2030</a>, growing at a CAGR of 14%.
Considering these conducive trends, let's take a look at the fundamentals of the three pharmaceutical picks.
AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>)
ABBV discovers, develops, manufactures, and sells pharmaceuticals worldwide. It offers a diverse range of pharmaceutical products, including treatments for autoimmune diseases, dermatology, rheumatology, oncology, neuroscience, eye care, gastroenterology, and endocrinology. Some of the products in its portfolio are HUMIRA, SKYRIZI, and RINVOQ.
In terms of the trailing-12-month <a href="https://www.investopedia.com/terms/e/ebit.asp">EBIT</a> margin, ABBV's 32.01% is considerably higher than the 2.78% industry average. Likewise, its 35.70% trailing-12-month levered FCF margin is significantly higher than the 1.66% industry average. Furthermore, its 69.66% trailing-12-month gross profit margin is 20.7% higher than the 57.70% industry average.
ABBV's net revenues for the fiscal second quarter that ended on June 30, 2024, increased 4.3% year-over-year to $14.46 billion. Its operating earnings for the period were $4 billion, and its adjusted earnings after tax were $4.71 billion. Additionally, its adjusted EPS was $2.65.
Street expects ABBV's revenue for the quarter ended September 30, 2024, to increase 2.4% year-over-year to $14.27 billion. Its EPS for the quarter ending December 31, 2024, is expected to grow 5.7% year-over-year to $2.95. Over the past year, ABBV's stock has gained 32.8% to close the last trading session at $196.82.
ABBV's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect strong prospects. It has an overall rating of A, translating to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #3 out of 159 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry. It has a B grade for Growth, Value, Stability, Sentiment, and Quality. <a href="https://stocknews.com/stock/ABBV/">Click here</a> to see ABBV's Momentum ratings.
Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY/">BMY</a>)
BMY discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.
On September 26, 2024, BMY announced FDA approval of COBENFY, a first-in-class treatment for schizophrenia. COBENFY introduces a new pharmacological approach, offering improved symptom reduction and safety.
In terms of the trailing-12-month levered FCF margin, BMY's 33.74% is significantly higher than the 1.66% industry average. Its 0.49x trailing-12-month asset turnover ratio is 19.9% higher than the 0.41x industry average. Also, its 76.18% trailing-12-month gross profit margin is 32% higher than the 57.70% industry average.
During the second quarter that ended June 30, 2024, BMY's total revenues increased 8.7% year-over-year to $12.20 billion. Its non-GAAP gross profit rose 9.6% from the year-ago value to $9.23 billion. For the same quarter, its non-GAAP net earnings attributable to BMY and non-GAAP EPS came in at $4.19 billion and $2.07, up 14.1% and 18.3% over the prior year's quarter, respectively.
For the quarter ended September 30, 2024, BMY's revenue is expected to increase 2.8% year-over-year to $11.27 million. Its EPS for fiscal 2025 is expected to rise 822.5% year-over-year to $7. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past three months, the stock has gained 32.9% to close the last trading session at $53.76.
BMY's POWR Ratings reflect a robust outlook. It has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Growth and a B for Value, Sentiment, and Quality. It is ranked #5 in the Medical – Pharmaceuticals industry. To see BMY's additional grades for Momentum and Stability, <a href="https://stocknews.com/stock/BMY/">click here</a>.
Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
On September 10, 2024, GILD announced a strategic collaboration with Genesis Therapeutics to leverage AI for discovering and developing novel small molecule therapies. GILD gained exclusive rights to develop and commercialize resulting products from the collaboration.
On August 14, 2024, GILD announced the FDA's accelerated approval of Livdelzi (seladelpar) for treating primary biliary cholangitis in adults. The drug demonstrated significant reductions in key biomarkers and pruritus compared to placebo.
In terms of the trailing-12-month EBITDA margin, GILD's 48.42% is 654.8% higher than the 6.41% industry average. Likewise, its 77.44% trailing-12-month gross profit margin is 34.2% higher than the 57.70% industry average. Additionally, its 0.48x trailing-12-month asset turnover ratio is 16.3% higher than the 0.41x industry average.
For the fiscal second quarter (ended June 30, 2024), GILD's total revenues increased 5.4% year-over-year to $ 6.95 billion. The company's non-GAAP operating income came in at $3.27 billion, up 43.4% from the previous year's quarter. In addition, its non-GAAP net income attributable to GILD stood at $2.52 billion or $2.01 per share, up 49.2% and 50% year-over-year, respectively.
Analysts expect GILD's revenue for the quarter ending December 31, 2024, to increase marginally year-over-year to $7.16 billion. Its EPS for fiscal 2025 is expected to grow 87.7% year-over-year to $7.14. It surpassed the Street EPS estimates in three of the trailing four quarters. Over the past three months, GILD's stock has gained 28.9% to close the last trading session at $84.74.
It's no surprise that GILD has an overall rating of A, which translates to a Strong Buy in our proprietary POWR Ratings system.
It has an A grade for Value and a B for Sentiment and Quality. It is ranked #5 out of 334 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. Beyond what we stated above, we also have given GILD grades for Growth, Momentum, and Stability. Get all the GILD's ratings <a href="https://stocknews.com/stock/GILD/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
ABBV shares were trading at $195.32 per share on Thursday afternoon, down $1.50 (-0.76%). Year-to-date, ABBV has gained 29.61%, versus a 20.31% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/abbv-bmy-gild-3-pharmaceutical-stocks-that-could-lead-the-next-drug-revolution/>3 Pharmaceutical Stocks That Could Lead the Next Drug Revolution</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Pharmaceutical Stocks That Could Lead the Next Drug Revolution

UMB to refile $6.4B lawsuit against Bristol-Myers by end of next week - report

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

Bristol-Myers trades in the green for seventh straight session

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

Bristol Myers Squibb: A High-Yield Bargain With Growth On The Horizon

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Barclays analyst Carter Gould maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report) on October 4 and set a price target of $43.0...

Barclays Sticks to Their Sell Rating for Bristol-Myers Squibb (BMY)

Top 10 rated U.S. value stocks per SA quant metrics

ABUS

ALPMF

ALPMY

AMGN

ANTX

ATHA

AVUV

BAYRY

BAYZF

BBIO

BIIB

BLUE

BMRN

BMYMP

CDTX

CHTR

CRBU

CRSP

CVAC

DFAT

DFIV

DFUV

EDIT

EXAS

FGEN

GLYC

HLVX

IBRX

INAB

JAVA

LXRX

NTLA

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

RXRX

SLRN

VIRX

Screenshot 2024-02-29 at 7.16.11 PM

ATNM

COEP

Here&#39;s How Coeptis Therapeutics Is Innovating Cell Therapy Approaches

Press Releases

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis

U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults

PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)

Comments

Bristol-Myers Squibb

Noticias

Últimas noticias sobre Bristol-Myers Squibb (NYSE:BMY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL